ArticleFrontiers in endocrinology2022
Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial.Diabetes & metabolism journal · 2026Trial
- The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study.Journal of diabetes research · 2026Trial
- Prediction model for metformin intolerance in Chinese elderly patients with type 2 diabetes: derivation and external validation in a cross‑sectional study.BMC endocrine disorders · 2026Article
- COVID-19 Infection and Gut Microbial Dysbiosis Among Filipinos with Type 2 Diabetes Mellitus.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Back to the Future: Repurposing Metformin, a Metabolically Active Drug, to Treat Mild-to-Moderate Ulcerative Colitis.Metabolites · 2026Review
- Metformin-Associated Gastrointestinal Intolerance: A Narrative Review of Mechanisms and Clinical Management.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- Review
- Type 2 Diabetes and the Multifaceted Gut-X Axes.Nutrients · 2025Review
- Gut microbiota-derived short-chain fatty acids mediate the antifibrotic effects of traditional Chinese medicine in diabetic nephropathy.Frontiers in endocrinology · 2025Review
- Metformin: From Diabetes to Cancer-Unveiling Molecular Mechanisms and Therapeutic Strategies.Biology · 2024Review
- Ensemble learning-assisted prediction of prolonged hospital length of stay after spine correction surgery: a multi-center cohort study.Journal of orthopaedic surgery and research · 2024Observational
- Review
- Nutrition at the Intersection between Gut Microbiota Eubiosis and Effective Management of Type 2 Diabetes.Nutrients · 2024Review
- Modern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.Frontiers in endocrinology · 2024Article
- The gut microbiota: emerging biomarkers and potential treatments for infertility-related diseases.Frontiers in cellular and infection microbiology · 2024Review
- Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Gastrointestinal discomfort is the most common adverse event in metformin treatment for type 2 diabetes. The mechanism of action of metformin is associated with gut microbiota. However, the gut microbial community structure related to metformin-induced gastrointestinal adverse events remains unclear. This study aimed to investigate it. Methods: 50 patients with newly diagnosed diabetes were treated with metformin 1500mg/d for 12 weeks. The patients were divided into two groups according to whether gastrointestinal adverse events occurred (group B) or did not occur (group A) after treatment. The fecal bacterial communities and short-chain fatty acids (SCFAs) were sequenced and compared. 70 diabetes mice were randomly divided into 8 groups and treated with metformin (Met), clindamycin (Clin) and/or SCFA, which were the Met+/Clin+, Met+/Clin-, Met-/Clin+, Met-/Clin-, Met+/SCFA+, Met+/SCFA-, Met-/SCFA+ and Met-/SCFA- group. After 4 weeks of metformin treatment, blood glucose, food intake, fecal SCFAs, gut microbiota and gut hormones were measured. Results: Metformin increased the abundance of Conclusions: Our data suggest that metformin promotes the secretion of intestinal hormones such as GLP-1 by increasing the abundance of SCFA-producing bacteria, which not only plays an anti-diabetic role, but also may causes gastrointestinal adverse events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.